Hemant Surgical H1 Profits Surge 241% to ₹18.8 Crore as Revenue Triples

Key numbers

1-Year Return	115.71%Price Performance
Market Cap	₹832.5 CrSmall Cap
P/E Ratio	45.76Sector P/E 55.13
RSI	62.34Neutral Zone

Key highlights

• Net profit grew 241.8% year-on-year to reach ₹18.8 crore in H1-27
• Revenue from operations surged to ₹276 crore, up from ₹64.6 crore in H1-26
• Operating margins remained stable at 9.8% despite the rapid scaling of business
• Company completed the acquisition of a 66.66% stake in Lifesenz Cancer Research Labs
• Consolidated total income for the half-year period stood at ₹279 crore

Consolidated Revenue Surge and Strategic Acquisition

Hemant Surgical Industries reported a substantial increase in operational scale during the first half of FY27, with consolidated revenue reaching ₹276 crore. This growth follows the execution of major contracts, including a ₹264.33 crore order from the Ministry of Health and Family Welfare for radiology equipment. The results also reflect the first period of consolidation for Lifesenz Cancer Research Labs Private Limited, in which the company acquired a 66.66% stake effective June 1, 2026.

This ₹1,999.80 lakh investment marks the company's expansion into specialized oncology research and diagnostics, complementing its existing medical equipment portfolio.

Operational Efficiency and Expenditure Profile

• Operating margins for H1-27 stood at 9.8%, a slight improvement over the 9.5% recorded in H2-26
• Cost of raw materials consumed reached ₹200.60 crore as production volumes scaled upward
• Employee benefit expenses increased to ₹6.67 crore due to business expansion and new subsidiary hiring
• Finance costs for the period were contained at ₹1.16 crore, down from ₹1.95 crore in H1-26
• Total consolidated expenses for the half-year were reported at ₹251.22 crore

Capital Deployment and Warrant Utilization

The company continues to deploy funds raised through preferential allotments for long-term growth. As of September 30, 2026, Hemant Surgical utilized ₹2,732.58 lakhs for capital expenditure, focusing on developing new facilities and expanding existing manufacturing capabilities. Additionally, ₹1,500 lakhs were allocated to augment working capital, while ₹1,700 lakhs were used for debt repayment.

The company is currently holding ₹1,380.92 lakhs in its bank account from these proceeds and expects to receive a further ₹886.50 lakhs from warrant holders upon the conversion of remaining instruments, which is expected by March 2027.

Board Approval and Segment Reporting

The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.

What to watch next

• Conversion of 6,00,000 outstanding warrants due by March 15, 2027
• Receipt of ₹8.86 crore in balance proceeds from warrant holders
• Ongoing execution milestones for the CMSS radiology equipment contract

“The Board of Directors of the Company has, at its Meeting held today i.e., November 14, 2026, considered and approved, inter-alia, the Un-audited Financial Results (standalone and consolidated) of the Company for the half year ended September 30, 2026.”

Hemant Surgical Industries · financial snapshot

Share price	₹638.5
Market capitalisation	₹832.50 Cr
Revenue (annual)	₹231.81 Cr
Net profit (annual)	₹18.19 Cr
P/E (TTM)	45.76×Sector 55.13×
Promoter holding	52.83%
FII holding	0%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.